The estimated Net Worth of Deepika Pakianathan is at least $6 Milion dollars as of 22 August 2024. Deepika Pakianathan owns over 105,244 units of Theravance Biopharma Inc stock worth over $852,476 and over the last 11 years he sold TBPH stock worth over $5,149,077. In addition, he makes $0 as Independent Director at Theravance Biopharma Inc.
Sign up
Deepika Pakianathan TBPH stock SEC Form 4 insiders trading
Deepika has made over 10 trades of the Theravance Biopharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 105,244 units of TBPH stock worth $151,551 on 22 August 2024.
The largest trade he's ever made was selling 906,178 units of Theravance Biopharma Inc stock on 31 May 2024 worth over $878,993. On average, Deepika trades about 84,710 units every 87 days since 2013. As of 22 August 2024 he still owns at least 105,244 units of Theravance Biopharma Inc stock.
You can see the complete history of Deepika Pakianathan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Deepika Pakianathan biography
Dr. Deepika R. Pakianathan Ph.D. serves as Independent Director of the Company. Prior to joining Delphi, Dr. Pakianathan was a Vice President in the healthcare group at J.P. Morgan where she was involved in several large healthcare M&A transactions and led public offerings for biotechnology companies. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Dr. Pakianathan received her Ph.D. and M.S. from Wake Forest University and her MSc and BSc from the University of Bombay . Dr. Pakianathan also currently serves on the boards of Calithera Biosciences, Inc., Karyopharm Therapeutics, Inc., and Mereo BioPharma Group, PLC.
How old is Deepika Pakianathan?
Deepika Pakianathan is 52, he's been the Independent Director of Theravance Biopharma Inc since 2020. There are 19 older and 8 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
What's Deepika Pakianathan's mailing address?
Deepika's mailing address filed with the SEC is 800 Chesapeake Dr, Redwood City, CA 94063, USA.
Insiders trading at Theravance Biopharma Inc
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, oraz Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
What does Theravance Biopharma Inc do?
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
What does Theravance Biopharma Inc's logo look like?
Complete history of Deepika Pakianathan stock trades at Calithera Biosciences Inc, Karyopharm Therapeutics Inc, Theravance Biopharma Inc oraz Mereo BioPharma plc
Theravance Biopharma Inc executives and stock owners
Theravance Biopharma Inc executives and other stock owners filed with the SEC include:
-
Rick Winningham,
Chairman of the Board, Chief Executive Officer -
Andrew Hindman,
Chief Financial Officer, Senior Vice President -
Bradford Shafer,
Executive Vice President, General Counsel, Secretary -
Brett Haumann,
Senior Vice President, Clinical Development and Chief Medical Officer -
Frank Pasqualone,
Senior Vice President and Chief Commercial Operations Officer -
Philip Worboys,
Senior Vice President - Research and Translational Science -
Rick E. Winningham M.B.A.,
Chairman & CEO -
Andrew Asa Hindman,
Sr. VP & CFO -
Bradford J. Shafer,
Exec. VP, Gen. Counsel & Sec. -
Andrew Asa Hindman M.B.A,
Sr. VP & CFO -
Rhonda F. Farnum,
Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs -
William Young,
Lead Independent Director -
Burton Malkiel,
Independent Director -
Donal O'Connor,
Independent Director -
Dean Mitchell,
Independent Director -
Susan Molineaux,
Independent Director -
Eran Broshy,
Independent Director -
Laurie Alsup,
Independent Director -
George Whitesides,
Independent Director -
Robert Gunderson,
Director -
Deepika Pakianathan,
Independent Director -
Vijay Sabesan,
Senior Vice President - Technical Operations -
Kenneth Pitzer,
Senior Vice President - Product Strategy and Commercial Planning -
Ann Brady,
President - Theravance Biopharma Ireland Limited -
Dr. Ann B. Brady Ph.D.,
Pres of Theravance Biopharma Ireland Limited -
Dr. Richard A. Graham Ph.D.,
Sr. VP of Devel. -
Daniel Long,
Head of Medicinal Chemistry -
Dr. Kenneth R. Pitzer,
Sr. VP of Product Strategy & Commercial Planning -
Dr. Phillip D. Worboys,
Sr. VP of Research & Translational Science -
Dennis O. Driver,
Sr. VP of HR, Organizational and Leadership Devel. -
Gail B. Cohen,
VP of Corp. Communications & Investor Relations -
Jeremy T Grant,
-
Renee D Gala,
VP-Finance -
Peter S Ringrose,
Director -
Junning Lee,
Sr. VP, Technical Operations -
Sharathchandra S Hegde,
SVP, Research -
Henrietta Fore,
Director -
Shehnaaz Suliman,
SVP, Corp Dev & Strategy -
Jeffrey David Jonker,
Senior VP, Corp. & Bus. Dev. -
Michael G Atieh,
Director -
Leonard M Blum,
Sr VP, Chief Comm. Officer -
Inc. Innoviva,,
10% owner -
Mathai Mammen,
SVP, Research & Early Clin Dev -
Rhonda Farnum,
SVP, COMM & MEDICAL AFFAIRS -
Richard A Graham,
SVP, RESEARCH & DEVELOPMENT -
Plc Gsk,
-
Aziz Sawaf,
SVP & CHIEF FINANCIAL OFFICER -
Brett A. Grimaud,
SVP, GEN COUNSEL AND SECRETARY -
Susannah Gray,
-
Aine Miller,
SVP, DEV & HEAD OF IRE OFFICE -
Eli Samaha,
10% owner